Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.
Canada's Transition Therapeutics is touting positive Phase II data for a once-a-week GLP-1 treatment, triggering a decision point for partner Eli Lilly, which bought into the program in a $247 million deal.
A downbeat 2015 in emerging markets for Eli Lilly is set to continue into the coming year and beyond, executives said, though some brands remain strong and will take up most of the company's efforts in those regions, particularly in China.
It was a "very quiet quarter overall" for Eli Lilly & Co., in the words of Bernstein analyst Tim Anderson. But the company expects things to get plenty more exciting if its diabetes med Jardiance wins a label change, an event it's anticipating for the second half of this year.
Since Eli Lilly closed its $5.4 billion deal last year to buy Novartis Animal Health, Lilly has been doing an in-depth evaluation of its global manufacturing operations. The conclusions it has reached are bad news for more than 100 workers at plants in Ireland and Scotland.
In this week's Dx Digest, Roche Diagnostics teamed up with pharma heavyweight Eli Lilly to create a new test for Alzheimer's. Quanterix is setting its sights on Asia for growth and is mulling an IPO to spur development of its diagnostic device, Simoa. And OncoCyte struck a deal with The Wistar Institute to market a liquid biopsy test for lung cancer.
Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance.
Last September, a big study showed that Eli Lilly and Boehringer Ingelheim's SGLT2 diabetes drug, Jardiance, could lower cardiovascular risks. Now, the companies are one step closer to adding that study data to the drug's label--a win that could rock the marketplace, not only in the SGLT2 drug class, but in competitor categories like DPP-4 meds.
Partners Eli Lilly and Incyte filed an oral rheumatoid arthritis treatment for FDA approval, hoping to launch an agent that can steal market share from blockbuster injectables.
Eli Lilly may have laid out 2016 guidance on Tuesday that fell short of analysts' expectations. But it had good news, too: Its Type 2 diabetes med, Jardiance, has already begun stealing market share from its SGLT2 rivals since the drugmaker and partner Boehringer Ingelheim unveiled positive new cardiovascular data.